JP2020523373A - ガルシノールの抗肥満の潜在能力 - Google Patents
ガルシノールの抗肥満の潜在能力 Download PDFInfo
- Publication number
- JP2020523373A JP2020523373A JP2019569248A JP2019569248A JP2020523373A JP 2020523373 A JP2020523373 A JP 2020523373A JP 2019569248 A JP2019569248 A JP 2019569248A JP 2019569248 A JP2019569248 A JP 2019569248A JP 2020523373 A JP2020523373 A JP 2020523373A
- Authority
- JP
- Japan
- Prior art keywords
- garcinol
- mammal
- fat
- bacteroides
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Confectionery (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021130804A JP2021185156A (ja) | 2017-06-15 | 2021-08-10 | ガルシノールの抗肥満の潜在能力 |
JP2022067326A JP2022097521A (ja) | 2017-06-15 | 2022-04-15 | ガルシノールの抗肥満の潜在能力 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762519949P | 2017-06-15 | 2017-06-15 | |
US62/519,949 | 2017-06-15 | ||
US201762523611P | 2017-06-22 | 2017-06-22 | |
US62/523,611 | 2017-06-22 | ||
PCT/US2018/037242 WO2018231923A1 (en) | 2017-06-15 | 2018-06-13 | Anti-obesity potential of garcinol |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021130804A Division JP2021185156A (ja) | 2017-06-15 | 2021-08-10 | ガルシノールの抗肥満の潜在能力 |
JP2022067326A Division JP2022097521A (ja) | 2017-06-15 | 2022-04-15 | ガルシノールの抗肥満の潜在能力 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020523373A true JP2020523373A (ja) | 2020-08-06 |
Family
ID=64659462
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019569248A Pending JP2020523373A (ja) | 2017-06-15 | 2018-06-13 | ガルシノールの抗肥満の潜在能力 |
JP2021130804A Pending JP2021185156A (ja) | 2017-06-15 | 2021-08-10 | ガルシノールの抗肥満の潜在能力 |
JP2022067326A Pending JP2022097521A (ja) | 2017-06-15 | 2022-04-15 | ガルシノールの抗肥満の潜在能力 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021130804A Pending JP2021185156A (ja) | 2017-06-15 | 2021-08-10 | ガルシノールの抗肥満の潜在能力 |
JP2022067326A Pending JP2022097521A (ja) | 2017-06-15 | 2022-04-15 | ガルシノールの抗肥満の潜在能力 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3638226A4 (de) |
JP (3) | JP2020523373A (de) |
KR (1) | KR102289324B1 (de) |
AU (1) | AU2018284354A1 (de) |
BR (1) | BR112019026824A2 (de) |
CA (1) | CA3066446A1 (de) |
MX (1) | MX2019014841A (de) |
WO (1) | WO2018231923A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102136335B1 (ko) * | 2020-03-24 | 2020-07-22 | (주)메디톡스 | 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도 |
KR102363092B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법 |
KR102191487B1 (ko) * | 2020-06-19 | 2020-12-15 | (주)메디톡스 | 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도 |
KR102363088B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 당뇨병 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 당뇨병 예방 또는 치료제 스크리닝 방법 |
KR102363098B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법 |
KR102363094B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 간질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 간질환 예방 또는 치료제 스크리닝 방법 |
KR102331485B1 (ko) | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
CN114605242A (zh) * | 2022-04-11 | 2022-06-10 | 澳门大学 | 间苯三酚类化合物的制备方法与药物、保健产品和食品 |
CN114847475B (zh) * | 2022-07-05 | 2022-11-29 | 广东金骏康生物技术有限公司 | 一种促进akk菌生长的发酵槐米粉的应用 |
CN115637242A (zh) * | 2022-10-20 | 2023-01-24 | 中南大学 | 微生物复合菌剂及其制备方法和赤泥原位生物脱碱的方法 |
CN116903760A (zh) * | 2023-05-25 | 2023-10-20 | 浙江大学 | 木耳多糖及其制备方法和抑制肥胖的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000044468A (ja) * | 1998-07-29 | 2000-02-15 | Kikkoman Corp | リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤 |
JP2004506657A (ja) * | 2000-08-17 | 2004-03-04 | サビンサ コーポレーション | 天然および合成hcaのバイオアベイラブルな組成物 |
US20120178801A1 (en) * | 2011-01-10 | 2012-07-12 | Muhammed Majeed | Compositions and its use in treating obesity or inducing weight loss |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011352073B2 (en) * | 2010-12-30 | 2015-12-24 | Sami Labs Limited | Hepatoprotectant activity of garcinol |
CA3092318A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
US9872840B2 (en) * | 2013-10-03 | 2018-01-23 | Delhi Institute Of Pharmaceutical Sciences And Research | Effect of garcinol in delaying the progression of diabetic nephropathy |
KR102356094B1 (ko) * | 2014-03-24 | 2022-01-26 | 주식회사 다이셀 | 약학 조성물 |
CA2934156A1 (en) * | 2015-11-10 | 2017-05-10 | Muhammed Majeed | Use of forskolin in the treatment of obesity |
-
2018
- 2018-06-13 BR BR112019026824-3A patent/BR112019026824A2/pt unknown
- 2018-06-13 WO PCT/US2018/037242 patent/WO2018231923A1/en unknown
- 2018-06-13 KR KR1020197038979A patent/KR102289324B1/ko active IP Right Grant
- 2018-06-13 JP JP2019569248A patent/JP2020523373A/ja active Pending
- 2018-06-13 CA CA3066446A patent/CA3066446A1/en active Pending
- 2018-06-13 EP EP18817304.1A patent/EP3638226A4/de active Pending
- 2018-06-13 AU AU2018284354A patent/AU2018284354A1/en active Pending
- 2018-06-13 MX MX2019014841A patent/MX2019014841A/es unknown
-
2021
- 2021-08-10 JP JP2021130804A patent/JP2021185156A/ja active Pending
-
2022
- 2022-04-15 JP JP2022067326A patent/JP2022097521A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000044468A (ja) * | 1998-07-29 | 2000-02-15 | Kikkoman Corp | リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤 |
JP2004506657A (ja) * | 2000-08-17 | 2004-03-04 | サビンサ コーポレーション | 天然および合成hcaのバイオアベイラブルな組成物 |
US20120178801A1 (en) * | 2011-01-10 | 2012-07-12 | Muhammed Majeed | Compositions and its use in treating obesity or inducing weight loss |
Non-Patent Citations (5)
Title |
---|
BIOSCI.BIOTECHNOL.BIOCHEM., vol. 72, JPN6021008114, 2008, pages 1772 - 1780, ISSN: 0004663783 * |
FOOD AND FUNCTION, vol. 3, JPN6021008118, 2012, pages 49 - 57, ISSN: 0004459447 * |
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, vol. 1, JPN6021008117, 2010, pages 175 - 181, ISSN: 0004459446 * |
NUTRAFOODS, vol. 8, JPN6021008116, 2009, pages 17 - 26, ISSN: 0004459445 * |
SCIENTIFIC REPORTS, vol. 6, JPN6021008115, 2016, pages 33566, ISSN: 0004459444 * |
Also Published As
Publication number | Publication date |
---|---|
JP2021185156A (ja) | 2021-12-09 |
KR20200012978A (ko) | 2020-02-05 |
WO2018231923A1 (en) | 2018-12-20 |
BR112019026824A2 (pt) | 2020-06-30 |
EP3638226A4 (de) | 2021-04-07 |
KR102289324B1 (ko) | 2021-08-12 |
EP3638226A1 (de) | 2020-04-22 |
MX2019014841A (es) | 2020-02-17 |
JP2022097521A (ja) | 2022-06-30 |
AU2018284354A1 (en) | 2020-01-16 |
CA3066446A1 (en) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020523373A (ja) | ガルシノールの抗肥満の潜在能力 | |
He et al. | Rhizoma Coptidis alkaloids alleviate hyperlipidemia in B6 mice by modulating gut microbiota and bile acid pathways | |
JP6954563B2 (ja) | 代謝障害を処置するための低温殺菌アッカーマンシアの使用 | |
Zhao et al. | Pomegranate peel polyphenols reduce chronic low-grade inflammatory responses by modulating gut microbiota and decreasing colonic tissue damage in rats fed a high-fat diet | |
Liu et al. | Grape seed proanthocyanidin extract ameliorates inflammation and adiposity by modulating gut microbiota in high‐fat diet mice | |
Tang et al. | A synbiotic consisting of Lactobacillus plantarum S58 and hull-less barley β-glucan ameliorates lipid accumulation in mice fed with a high-fat diet by activating AMPK signaling and modulating the gut microbiota | |
Zhang et al. | 25‐Hydroxyvitamin D3‐enhanced PTPN 2 positively regulates periodontal inflammation through the JAK/STAT pathway in human oral keratinocytes and a mouse model of type 2 diabetes mellitus | |
JP2018532779A (ja) | 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル | |
Ge et al. | Luteolin cooperated with metformin hydrochloride alleviates lipid metabolism disorders and optimizes intestinal flora compositions of high-fat diet mice | |
Yan et al. | Oryzanol alleviates high fat and cholesterol diet-induced hypercholesterolemia associated with the modulation of the gut microbiota in hamsters | |
Dai et al. | Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice | |
KR20160069492A (ko) | 박테로이데스 에시디페시언스를 유효성분으로 포함하는, 대사성 질환 예방 또는 치료용 약학적 조성물 | |
US20200030388A1 (en) | Compositions for modifying gut microbiota | |
Ding et al. | N-Acetylcysteine alleviates high fat diet-induced hepatic steatosis and liver injury via regulating the intestinal microecology in mice | |
US20180360776A1 (en) | Anti-obesity potential of garcinol | |
Sheykhsaran et al. | Gut microbiota and obesity: an overview of microbiota to microbial-based therapies | |
Yan et al. | Gut dysbiosis correction contributes to the hepatoprotective effects of Thymus quinquecostatus Celak extract against alcohol through the gut–liver axis | |
Xiao et al. | Neohesperidin dihydrochalcone ameliorates high-fat diet-induced glycolipid metabolism disorder in rats | |
Zhang et al. | M2 macrophages infusion ameliorates obesity and insulin resistance by remodeling inflammatory/macrophages' homeostasis in obese mice | |
JP2021527669A (ja) | 線維症の軽減又は治療のための組成物及び方法 | |
Zhang et al. | Fermented soybean powder containing Bacillus subtilis SJLH001 protects against obesity in mice by improving transport function and inhibiting angiogenesis | |
He et al. | Mangiferin alleviates trimethylamine-N-oxide (TMAO)-induced atherogenesis and modulates gut microbiota in mice | |
Zhang et al. | MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis | |
Wen et al. | Alleviating Effect of Mulberry Leaf 1-Deoxynojirimycin on Resistin-Induced Hepatic Steatosis and Insulin Resistance in Mice | |
Li et al. | Astragaloside IV alleviates macrophage senescence and d-galactose-induced bone loss in mice through STING/NF-κB pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200407 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200407 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210308 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210810 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211215 |